KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification
News Oct 19, 2009
KINAXO Biotechnologies GmbH and Bayer Vital GmbH announced that they will enter into collaboration. KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® for the identification of novel biomarkers in a clinical trial conducted by Bayer Vital.
KINAXO’s phosphoproteomics platform allows annotation and quantification of regulated phosphorylation sites. Since the majority of targeted compounds used as anti-cancer drugs influence cellular signal transduction pathways, analysis of phosphorylation patterns in relation to drug administration reveals a compound’s molecular mode of action.
Characteristic phosphorylation sites predicting response to treatment, resistance mechanism or synergistic effects can hereby be identified as biomarkers which allow for personalized treatment plans.
Accompanying a clinical trial for the multi-kinase inhibitor Nexavar® in Acute Myeloid Leukemia (AML), KINAXO will apply its phosphoproteomics technology to reveal the drug’s influence on cellular phosphorylation patterns and to search for novel predictive biomarkers.
Nexavar® is already approved for the treatment of hepatocellular (HCC) and renal cell carcinoma (RCC) and shows promising effects in several other indications, amongst them AML, the most common type of leukemia in adults. Despite considerable efforts over the last decades, therapeutic outcome in AML therapy has improved only modestly and remains dismal, with a high number of patients being non-responsive to standard treatment or recurrent.
Application of KINAXO’s phosphoproteomics technology could thus turn out to be a valuable tool to discover predictive biomarkers that foretell therapeutic outcome in patients. Furthermore, quantitative phosphoproteomics will be applied to investigate the molecular efficiency of potential combination therapies in which Nexavar® will be administered together with other targeted drugs to effectively fight cancer. In turn, individualized therapeutic strategies could then improve overall treatment outcome for malignant diseases, such as AML.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE